Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Investigation reveals sperm donor passed on cancer risk to dozens of children across Europe - 2How a niche Catholic approach to infertility treatment became a new talking point for MAHA conservatives
- 3New method spots signs of Earth's primordial life in ancient rocks
- 4Esteem Stuffed Gaming Workstations to Consider
- 5Tickets for 'Stranger Things' Season 5 finale, to be shown in movie theaters on New Year's Eve, go on sale today. Here's how you can save your seat.
- Boeing's troubled capsule won't carry astronauts on next space station flight
- VPN Administrations for Online Protection
- Mont Blanc road tunnel reopens to traffic after 15 weeks of repairs
- Vote in favor of the Web-based Work out schedule to Keep You Fit and Sound
- Witness the elegance of the cosmic butterfly in a remarkable telescope photo
- Banks for High Fixed Store Rates: Amplify Your Reserve funds
- Satellite constellations could obscure most space telescope observations by late 2030s: 'That part of the image will be forever lost'
- Northern lights chances rise for Christmas as space weather remains unsettled
- Sound and Delightful: 12 Nutritious Smoothie Recipes
